Non-Interventional Post-Authorisation Safety Study (PASS) survey to evaluate the effectiveness of the Isatuximab Educational Materials, to minimise the Risk of Interference for blood typing (minor antigen) (positive indirect Coombs’ test).

03/05/2022
23/04/2024
EU PAS number:
EUPAS46988
Study
Finalised

ENCePP Code of conduct

No
Data sources

Data sources (types)

Other

Data sources (types), other

LiveTracker™ panel
Use of a Common Data Model (CDM)

CDM mapping

No
Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown
Data characterisation

Data characterisation conducted

No